Organisation paid for research Program year 2025 Source: CMS Open Payments

Northridge Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,450,224

137 payments

Through program year 2025, Northridge Clinical Trials is reported as receiving $1,450,224 in research payments, across 137 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$543,472	70
2024	Research	$891,571	64
2023	Research	$15,181	3

Breakdown

Who paid Research payments · program years 2023–2025

Pfizer Inc. $565,344 32 payments
Amgen Inc. $241,183 8 payments
Sanofi US Services Inc. $155,682 13 payments
GlaxoSmithKline, LLC. $124,190 48 payments
Eli Lilly and Company $104,654 3 payments
Almirall LLC $61,205 22 payments
Sun Pharmaceutical Industries Inc. $59,590 4 payments
Ucb SA $57,519 2 payments
Novartis Pharmaceuticals Corporation $38,857 1 payment
E.R. Squibb & Sons, L.L.C. $28,000 2 payments

Studies the money was for Research payments · program years 2023–2025

A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $565,344 32 payments
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $155,682 13 payments
A Phase 2B, Randomized, Double-Blind, Parallel Group, Placebo Controll $114,690 46 payments
VOYAGER P3 AD Vaccine Study $92,053 2 payments
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $86,611 1 payment
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $83,439 1 payment
RXLC 2118 $73,590 6 payments
M-27134-01 $61,205 22 payments
A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis $57,519 2 payments
ASCEND P3 AD Extension $44,064 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.